• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Intrepid Home Health

Anonymous

Guest
any feedback on this company. from what I have seen and heard it seems like a second rate company at best! micro management, cheap, no upward mobility, distrust between ops and sales and terrible comission plan.